CorMedixvsMerck & Company

CRMD and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

CorMedix (CRMD) has a market value of $356M and Merck & Company (MRK) $341B. Over the last year, with dividends, CRMD moved -54.9% and MRK +52.7%. The P/E is 5.6 for CRMD and 138.9 for MRK. Dividend yield: CRMD none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CRMD$356M

    MRK$341B

    MRK is 958 times CRMD

  • Revenue, 12 months

    CRMD$412M

    MRK$67.4B

    MRK is 163 times CRMD

  • Net income, 12 months

    CRMD$64M

    MRK$2.5B

    MRK is 38 times CRMD

  • Operating margin

    CRMD38.6%

    MRK–

  • ROIC

    CRMD27.3%

    MRK3.9%

    23.4 points apart

  • P/E

    CRMD5.6

    MRK138.9

    MRK is 25 times CRMD

  • Dividend yield

    CRMD0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    CRMD-11.2%

    MRK+94.3%

    105.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CRMD-11.3%

MRK+94.3%

10020030020222023202420252026
Returns by period
PeriodCRMDWith dividendsMRKWith dividends
1 year since November 17, 2025-54.9%Price -54.9%+52.7%Price +48.4%
3 years since November 17, 2023+12.2%+3.9% a yearPrice +12.2%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021-11.2%-2.4% a yearPrice -11.2%+94.3%+14.2% a yearPrice +66.8%
10 years since November 18, 2016-51.1%-6.9% a yearPrice -51.1%+216.6%+12.2% a yearPrice +133.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CRMDCorMedixMRKMerck & Company

Valuation

CRMDMRK
Valuation
Price$4.50$137.78
Market value$356M$341B
Enterprise value (EV)$721.4K$385B
P/E5.6138.9
P/E, 5-year median–14.8
P/B0.87.6
EV/EBIT–80.8
Free cash flow yield86.5%4.3%

Results and growth

CRMDMRK
Results and growth
Revenue, 12 months$412M$67.4B
Net income, 12 months$64M$2.5B
Free cash flow, 12 months$308M$14.7B
Earnings per share, 12 months$0.81$0.98
Revenue growth, year on year617.0%1.3%
Revenue growth a year, past+319.8%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CRMDMRK
Margins and returns on capital
Gross margin77.5%71.8%
Operating margin38.6%–
Net margin15.5%3.6%
ROIC27.3%3.9%
ROE14.9%5.2%

Balance sheet

CRMDMRK
Balance sheet
Cash$355M$9.7B
Total debt$144.6K$53.8B
Net debt / EBITDA-2.25.7
Interest cover57.2×2.4×

Dividends and buybacks

CRMDMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CRMD or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, CorMedix or Merck & Company?

By market value, Merck & Company ($341B) is about 957.6 times CorMedix ($356M), at today's prices.

How did CRMD and MRK stock do over the last 10 years?

Since November 18, 2016, CRMD's price moved -51.1% and MRK's +133.4%. With dividends: CRMD -51.1% (-6.9% a year), MRK +216.6% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, CRMD or MRK?

The dividend yield at today's price is none for CorMedix and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of CRMD and MRK?

At today's price, the P/E is 5.6 for CRMD and 138.9 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, CorMedix or Merck & Company?

Over the last twelve months, the net margin was 15.5% for CorMedix and 3.6% for Merck & Company, and the operating margin 38.6% and –. Revenue was $412M and $67.4B.

Which is the better investment, CorMedix or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.